Our Western blotting analysis shows that the overexpression of NF-κB p65 can be significantly inhibited by treating with NCPB, which indicated that NCPB’s effect on the NF-κB pathway may underlie the protective effects of NCPB on the development of SIRS after PH. Here, NFKB1 is linked to systemic inflammatory response syndrome.